Bisantrene/ Zantrene is a phase 3 asset.
Race oncology’s drug has been given to over 1000 patients, was past fully approved for AML , in France. (Lederle developed Bisantrene / Zantrene over several decades, >20years, to be a less cardio- toxic oncology drug.)
Doxorubicin being a horrible, known to cause heart damage oncology drug , although highly effective at killing cancer cells.
It is still now a standard of care drug , although oncologists try to limit its dose which renders the cancer killing capacity also lower , even where patients are relapsed and have impossible to fully treat cancers. AML, Bladder cancers, Ovarian. refractory breast especially, and others.
Zantrene has been in over 40 clinical trials, actually over 60 trials , including 3 phase 3 trials.
We don’t have a totally experimental drug.
Dose is well- understood, and administration historically , + the safety profile, safety also is very known and proven.
Expand
